Left lobe adult-to-adult living donor liver transplantation: small grafts and hemiportocaval shunts in the prevention of small-for-size syndrome.
Adult-to-adult living donor liver transplantation (AA-LDLT) has better outcomes when a graft weight to recipient weight ratio (GW/RW) > 0.8 is selected. A smaller GW/RW may result in small-for-size syndrome (SFSS). Portal inflow modulation seems to effectively prevent SFSS. Donor right hepatectomy is associated with greater morbidity and mortality than left hepatectomy. In an attempt to shift the risk away from the donor, we postulated that left lobe grafts with a GW/RW < 0.8 could be safely used with the construction of a hemiportocaval shunt (HPCS). We combined data from 2 centers and selected suitable left lobe living donor/recipient pairs. Since January 2005, 21 patients underwent AA-LDLT with left lobe grafts. Sixteen patients underwent the creation of an HPCS between the right portal vein and the inferior vena cava. The portocaval gradient (portal pressure - central venous pressure) was measured before the unclamping of the shunt and 10 minutes after unclamping. The median actual graft weight was 413 g (range = 350-670 g), and the median GW/RW was 0.67 (range = 0.5-1.0). The portocaval gradient was reduced from a median of 18 to 5 mmHg. Patient survival and graft survival at 1 year were 87% and 81%, respectively. SFSS developed in 1 patient, who required retransplantation. Two patients died at 3 and 10 months from a bile leak and fungal sepsis, respectively. The median recipient bilirubin level and INR were 1.7 mg/dL and 1.1, respectively, at 4 weeks post-transplant. One donor had a bile leak (cut surface). This is the first US series of small left lobe AA-LDLT demonstrating that the transplantation of small grafts with modulation of the portal inflow by the creation of an HPCS may prevent the development of SFSS while at the same time providing adequate liver volume. As it matures, this technique has the potential for widespread application and could positively effect donor safety, the donor pool, and waiting list times.
Botha
Jean F
JF
Division of Transplantation, Department of Surgery, University of Nebraska Medical Center, Omaha, NE 68198, USA. jbotha@unmc.edu
Langnas
Alan N
AN
Campos
B Daniel
BD
Grant
Wendy J
WJ
Freise
Christopher E
CE
Ascher
Nancy L
NL
Mercer
David F
DF
Roberts
John P
JP
D000328:Adult; D000368:Aged; D001783:Blood Flow Velocity / Q000502:physiology; D016208:Databases, Factual; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000401:mortality; D006085:Graft Survival / Q000502:physiology; D006498:Hepatectomy / Q000379:methods; D006501:Hepatic Encephalopathy / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008102:Liver Circulation / Q000502:physiology*; D008107:Liver Diseases / Q000401:mortality / Q000601:surgery*; D008115:Liver Regeneration / Q000502:physiology; D016031:Liver Transplantation / Q000379:methods* / Q000401:mortality; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D011169:Portal Vein / Q000502:physiology; D011170:Portasystemic Shunt, Surgical / Q000379:methods*; D011183:Postoperative Complications / Q000401:mortality / Q000517:prevention & control; D012086:Reoperation; D014682:Vena Cava, Inferior / Q000502:physiology; D055815:Young Adult
D007166:Immunosuppressive Agents